Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association (original) (raw)
Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915–931. ArticleCASPubMed Google Scholar
Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003; 102: 1613–1618. ArticleCASPubMed Google Scholar
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837–845. ArticlePubMed Google Scholar
Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926–933. CASPubMed Google Scholar
Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639–1647. ArticleCASPubMed Google Scholar
Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507–1515. ArticleCASPubMed Google Scholar
Marcucci G, Haferlach T, Dohner H . Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475–486. ArticleCASPubMed Google Scholar
Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25: 3337–3343. ArticleCASPubMed Google Scholar
Bullinger L, Kronke J, Schon C, Radtke I, Urlbauer K, Botzenhardt U et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 2010; 24: 438–449. ArticleCASPubMed Google Scholar
Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65: 375–378. CASPubMed Google Scholar
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2009; 115: 453–474. ArticlePubMed Google Scholar
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918. ArticleCASPubMed Google Scholar
Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746. ArticlePubMed Google Scholar
Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739. ArticleCASPubMed Google Scholar
Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754. ArticleCASPubMed Google Scholar
Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009; 113: 5090–5093. ArticleCASPubMed Google Scholar
Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28: 570–577. ArticleCASPubMed Google Scholar
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE . Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28: 2739–2747. ArticleCASPubMed Google Scholar
Pabst T, Eyholzer M, Fos J, Mueller BU . Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100: 1343–1346. ArticleCASPubMedPubMed Central Google Scholar
Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469–2475. ArticleCASPubMed Google Scholar
Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R . Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088–3091. ArticleCASPubMedPubMed Central Google Scholar
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066. ArticleCASPubMedPubMed Central Google Scholar
Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225–234. ArticleCASPubMedPubMed Central Google Scholar
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433. ArticleCASPubMedPubMed Central Google Scholar
Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309–315. ArticleCASPubMed Google Scholar
Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723–3731. ArticleCASPubMed Google Scholar
Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889–2896. ArticleCASPubMed Google Scholar
Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia-stability during disease evolution and the clinical implication. Blood 2011; e-pub ahead of print 10 November 2011; doi:10.1182/blood-2011-07-369934. ArticlePubMed Google Scholar
Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593–5603. ArticleCASPubMed Google Scholar
Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010; 28: 808–814. ArticleCASPubMed Google Scholar
Thomas X, Raffoux E, Botton S, Pautas C, Arnaud P, de Revel T et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21: 453–461. ArticleCASPubMed Google Scholar
International system for cytogenetic nomenclature: guidelines for cancer cytogenetics. In: Mitelmann F (ed). Supplement to an International System for Human Cytogenetic Nomenclature. S. Karger: Basel, Switzerland, 1995.
Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447–1452. ArticleCASPubMed Google Scholar
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT . Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983–988. ArticleCASPubMed Google Scholar
Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618–3620. ArticleCASPubMed Google Scholar
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717–2723. ArticleCASPubMed Google Scholar
Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009; 115: 3719–3727. ArticleCASPubMed Google Scholar
Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2011; 28: 3717–3723. Article Google Scholar
Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C . Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011; 117: 3696–3697. ArticleCASPubMed Google Scholar
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649. ArticlePubMed Google Scholar
Larochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget 2011; 2: 850–861. ArticlePubMedPubMed Central Google Scholar
Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 204–209. ArticlePubMedPubMed Central Google Scholar
Thol F, Heuser M, Damm F, Klusmann JH, Reinhardt K, Reinhardt D . DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 2011; 96: 1238–1240. ArticlePubMedPubMed Central Google Scholar
Shiba N, Taki T, Park MJ, Shimada A, Sotomatsu M, Adachi S et al. DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia. Br J Haematol 2011; e-pub ahead of print 8 October 2011; doi: 10.1111/j.1365-2141.2011.08879.x. ArticlePubMed Google Scholar
Ehrlich M . The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 2003; 109: 17–28. ArticleCASPubMed Google Scholar
Xu GL, Bestor TH, Bourc’his D, Hsieh CL, Tommerup N, Bugge M et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402: 187–191. ArticleCASPubMed Google Scholar
Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13–27. ArticleCASPubMedPubMed Central Google Scholar
Thol F, Damm F, Krauter J, Ganser A, Heuser M . Reply to S. Masuda. J Clin Oncol 2011; 29: 4593–4594. Article Google Scholar
Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011; 25: 1217–1219. ArticleCASPubMed Google Scholar
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153–1158. ArticleCASPubMedPubMed Central Google Scholar